Investor Relations
Welcome to Alzinova AB’s IR pages.
Alzinova AB is a company specializing in the treatment of Alzheimer’s disease – one of our major health scourges, without effective treatment options.
Latest press releases
- 2020-11-16 | Regulatory Last day of trading in paid subscription units (Sw.BTU) and first day of trading for TO2 2020/2022
- 2020-11-04 | Regulatory Alzinova AB announces the study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 at a scientific congress.